SOLO-3 Adds To AZ/MSD’s Lynparza’s Ovarian Cancer Success Tally But Impact Minimal
Companies plan to discuss SOLO-3 data with the US FDA after Lynparza shows a benefit in third-line ovarian cancer, but commercial impact will be slight.
Companies plan to discuss SOLO-3 data with the US FDA after Lynparza shows a benefit in third-line ovarian cancer, but commercial impact will be slight.